Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Stroke may trigger younger brain patterns in unaffected regions

25

Mar 2026

Stroke may trigger younger brain patterns in unaffected regions

In a new study published in The Lancet Digital Health, scientists at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) have discovered that the brains of people who experience severe physical impairment after a stroke may reorganize themselves in unexpected ways, showing signs of "younger" brain structure in undamaged regions as they adapt to injury.

CDC tracks SARS-CoV-2 BA.3.2 global rise and finds early signals in U.S. wastewater

25

Mar 2026

CDC tracks SARS-CoV-2 BA.3.2 global rise and finds early signals in U.S. wastewater

CDC surveillance shows that the highly divergent SARS-CoV-2 variant BA.3.2 spread to at least 23 countries and was detected in U.S. travelers, patients, airplane wastewater, and wastewater samples across multiple states. The report highlights wastewater and traveler-based genomic surveillance as early warning tools while noting that BA.3.2 has immune-evasion potential but has not rapidly displaced other circulating lineages.

Study finds AI-generated X-rays can fool radiologists and chatbots

25

Mar 2026

Study finds AI-generated X-rays can fool radiologists and chatbots

Researchers found that both radiologists and multimodal AI models had only moderate success distinguishing synthetic radiographs from real clinical images, even when told fakes were present. The study warns that increasingly realistic AI-generated X-rays could be misused in medicine, research, insurance, and litigation, strengthening the case for watermarking, clinician training, and dedicated detection tools.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.